TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3278498

Group type: EXPERIMENTAL
Intervention: Indomethacin (25‐50 mg bolus plus infusion, 5‐7.5 mg h‐1) in lactated Ringer solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lactated Ringer solution
Number of subjects: 100
Study: 30573769

Group type: EXPERIMENTAL
Intervention: Interactive group format treatment (6 sessions, 2 hours each, one session per week)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Interactive group format treatment
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 81
Study: 28800067

Group type: EXPERIMENTAL
Intervention: Mountain hiking
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Indoor treadmill walking
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 42
Study: 26258447

Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Light touch
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rough touch
Number of subjects: 11

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Movement distance and peak velocity during forward-reaching task
Number of subjects: 11
Study: 23243212

Group type: EXPERIMENTAL
Intervention: Sitaxentan
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 21778256

Group type: EXPERIMENTAL
Intervention: Higher-caloric exercise condition (longer-distance walking)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lower-caloric-expenditure exercise group
Number of subjects: 38
Study: 18712387

Group type: EXPERIMENTAL
Intervention: Proximal midshaft centralising device (PCD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Distal centralising device (DCD)
Number of subjects: 30
Study: 17147285

Group type: EXPERIMENTAL
Intervention: Thymectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural progression of the disease
Number of subjects: 0
Study: 31347489

Group type: EXPERIMENTAL
Intervention: Test canagliflozin formulation (100 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Reference canagliflozin formulation (100 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 55
Study: 10599729

Group type: EXPERIMENTAL
Intervention: GH treatment group A, 4 IU/m2 x day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH treatment group B, first year 4 and thereafter 6 IU/m2 x day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH treatment group C, first year 4, second year 6, and thereafter 8 IU/m2 x day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH treatment groups A, B, C
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH treatment group A
Number of subjects: 68
Study: 8738724

Group type: EXPERIMENTAL
Intervention: recombinant alpha 2b interferon (3 MIU, subcutaneously, three times a week for 4 months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: no treatment (control group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: recombinant alpha 2b interferon
Number of subjects: 41
Study: 1932297

Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ceftazidime with amikacin (1.5 g/day)
Number of subjects: 90
Study: 6211997

Group type: EXPERIMENTAL
Intervention: Althesin infusion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 22
Study: 30996060

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study: 29441949

Group type: EXPERIMENTAL
Intervention: Caffeine (first day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 42
Study: 27480145

Group type: COMPARATOR
Intervention: Fluorouracil-radiotherapy
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: mFOLFOX6-radiotherapy
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Number of subjects: 495
Study: 24622752

Group type: EXPERIMENTAL
Intervention: Weight control and physical activity intervention (15 visits from a dietitian over 3 years)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (4 visits over 3 years)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Weight control and physical activity intervention
Number of subjects: 171
Study: 22100576

Group type: EXPERIMENTAL
Intervention: darunavir-ritonavir
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: fosamprenavir-ritonavir
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy, non-opioid-dependent volunteers)
Number of subjects: 21
Study: 20339034

Group type: COMPARATOR
Intervention: Segmental pulmonary vein isolation (PVI)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation plus left atrial linear ablation (CPVA+LALA)
Number of subjects: 66
Study: 18358082

Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Tramadol ER 400 mg
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1011
Study: 16463883

Group type: EXPERIMENTAL
Intervention: Non-invasive cerebrovascular autoregulation (CA) monitoring using ultrasonic 'time-of-flight' monitor (Vittamed)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Invasive cerebrovascular autoregulation (CA) monitoring
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Non-invasive cerebrovascular autoregulation (CA) monitoring
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Non-invasive cerebrovascular autoregulation (CA) estimation
Number of subjects: 13
Study: 12849808

Group type: EXPERIMENTAL
Intervention: Unopposed hormone therapy (CEE)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Opposed hormone therapy (CEE and medroxyprogesterone acetate)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Tibolone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 108
Study: 10380943

Group type: EXPERIMENTAL
Intervention: Continuous sun exposure due to residence or occupation
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Living in the city but spending 50% of time in rural areas for holidays
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Sunbathing more than 30 times a year
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Outdoor leisure time with exposure greater than 60 units in the last 2 years
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Construction workers
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Freckle count
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Mole count
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Working as a farmer
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Use of sunscreens
Number of subjects: 351
Study: 8983399

Group type: EXPERIMENTAL
Intervention: Epristeride 5 mg oral dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epristeride 4.5 mg intravenous infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epristeride 5 mg oral dose and 4.5 mg intravenous infusion
Number of subjects: 12
Study: 1750594

Group type: EXPERIMENTAL
Intervention: Epidural morphine (double-blind, placebo-controlled)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (patient-controlled analgesia)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Epidural morphine (open administration)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 6174719

Group type: EXPERIMENTAL
Intervention: Oral iron therapy for 6 to 8 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nonanemic infants (control group)
Number of subjects: 68
Study: 31402114

Group type: EXPERIMENTAL
Intervention: Guselkumab (100 mg at weeks 0 and 4 then every 8 weeks)
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Secukinumab (300 mg at weeks 0, 1, 2, 3, and 4, then every 4 weeks)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Secukinumab
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Guselkumab and Secukinumab
Number of subjects: 1048
Study: 28674348

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg) in EAC group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rabeprazole (10 mg) in RAC group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both EAC and RAC regimens
Number of subjects: 200
Study: 26386993

Group type: EXPERIMENTAL
Intervention: COSS (conversation roadmap, monitoring of cooperation, extra occupational physician support)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Common practice
Number of subjects: 64
Study: 24977401

Group type: EXPERIMENTAL
Intervention: Sublingual alprazolam (0.5 mg)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Oral alprazolam (0.5 mg)
Number of subjects: 220
Study: 22545364

Group type: EXPERIMENTAL
Intervention: Triamcinolone ointment (twice a day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral atorvastatin (20 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo atorvastatin tablet (daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo triamcinolone ointment (twice a day)
Number of subjects: 30
Study: 21535498

Group type: COMPARATOR
Intervention: White Bread (WB) 57 g, 160 cal, 1 g fiber
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Raw Cranberries (RC) 55 g, 21 cal, 1 g fiber
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sweetened Dried Cranberries (SDC) 40 g, 138 cal, 2.1 g fiber
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sweetened Dried Cranberries with Less Sugar (SDC‐LS) 40 g, 113 cal, 1.8 g fiber + 10 g polydextrose
Number of subjects: 13

Group type: COMPARATOR
Intervention: White Bread (WB)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sweetened Dried Cranberries (SDC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Raw Cranberries (RC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sweetened Dried Cranberries with Less Sugar (SDC‐LS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Raw Cranberries (RC) and Sweetened Dried Cranberries with Less Sugar (SDC‐LS)
Number of subjects: 13
Study: 17606812

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 1775
Study: 16051497

Group type: EXPERIMENTAL
Intervention: Controlled doses of computer work involving prolonged static posture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled doses of computer work involving increased typing speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled doses of computer work involving increased typing force
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (not specified in detail)
Number of subjects: 0
Study: 11940749

Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation plus Pressure Support (SIMV-PS)
Number of subjects: 10
Study: 10076111

Group type: EXPERIMENTAL
Intervention: Intradermal injection of normal saline solution
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Self-selected music
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 1550777

Group type: EXPERIMENTAL
Intervention: VMBCP
Number of subjects: 91

Group type: COMPARATOR
Intervention: VAD
Number of subjects: 91
Study: 2864073

Group type: EXPERIMENTAL
Intervention: Celiprolol (0.15 mg/kg/5 min iv)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celiprolol (0.3 mg/kg/5 min iv)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (0.1 mg/kg/5 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31391682

Group type: EXPERIMENTAL
Intervention: Chlorophytum borivilianum (CB) 3 g/day
Number of subjects: 60
Study: 29688826

Group type: EXPERIMENTAL
Intervention: Balloon dilation of affected sinus ostia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balloon dilation in the nasal cavity (placebo)
Number of subjects: 0
Study: 26965722

Group type: EXPERIMENTAL
Intervention: Epidural block (group E&G) with continuous epidural and general anaesthesia, using ropivacaine for intraoperative and postoperative blocks.
Number of subjects: 70

Group type: COMPARATOR
Intervention: General anaesthesia only (group G) with remifentanil for analgesia.
Number of subjects: 70
Study: 26043363

Group type: EXPERIMENTAL
Intervention: 3-D camera system
Number of subjects: 2

Group type: COMPARATOR
Intervention: 2-D camera system
Number of subjects: 2
Study: 23673093

Group type: EXPERIMENTAL
Intervention: Compliance with blood cultures before antibiotics protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance with ≥5 protocols in the 6-hour resuscitation bundle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall compliance during 6-hr resuscitation and 24-hour management bundles
Number of subjects: 0
Study: 21599820

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) and stavudine (d4T)
Number of subjects: 911

Group type: COMPARATOR
Intervention: Control group (no LA/SHL)
Number of subjects: 911
Study: 18843436

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 17175635

Group type: EXPERIMENTAL
Intervention: Arginine treatment (0.4 g x kg(-1) x d(-1) orally for 7 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (tyrosine)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Arginine treatment and Placebo
Number of subjects: 86
Study: 12636896

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) in ICU
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) in ward
Number of subjects: 466
Study: 10612763

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting
Number of subjects: 132

Group type: COMPARATOR
Intervention: Continuous open incision
Number of subjects: 132
Study: 10219183

Group type: EXPERIMENTAL
Intervention: Preventive oral protocol consisting of elimination of bacterial plaque, mouthwash with chlorhexidine 0.12%, topical application of iodopovidone, and nystatin 500,000 units.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Palliative treatment for complications (Group I).
Number of subjects: 96
Study: 7942575

Group type: EXPERIMENTAL
Intervention: Diet + Aerobic exercise (DA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diet + Resistance exercise (DR)
Number of subjects: 24
Study: 3359824

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage with 200 ml of 25 degrees C normal saline solution
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage with 200 ml of 37 degrees C normal saline solution
Number of subjects: 27

Group type: COMPARATOR
Intervention: Routine bronchoscopic examination
Number of subjects: 27
Study: 29627188

Group type: EXPERIMENTAL
Intervention: Infants of black mothers
Number of subjects: 420

Group type: COMPARATOR
Intervention: Maternal race (black)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Breast milk diet
Number of subjects: 420

Group type: COMPARATOR
Intervention: Public insurance status
Number of subjects: 420

Group type: COMPARATOR
Intervention: Bronchopulmonary dysplasia
Number of subjects: 420
Study: 29200983

Group type: EXPERIMENTAL
Intervention: PROHIGH (2.9 g.kg‐1.d‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: PROMOD (1.8 g.kg‐1.d‐1)
Number of subjects: 14
Study: 25689594

Group type: EXPERIMENTAL
Intervention: PPV/CI guided group (target PPV <12%, CI >2.5 L/min/m², MAP >70 mmHg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: MAP-guided group (target MAP >70 mmHg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PPV/CI group
Number of subjects: 31

Group type: COMPARATOR
Intervention: MAP-guided group
Number of subjects: 31
Study: 23517178

Group type: EXPERIMENTAL
Intervention: Betahistine (48 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20627917

Group type: EXPERIMENTAL
Intervention: Automatic positive airway pressure (APAP) titration
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Laboratory APAP titration
Number of subjects: 249

Group type: COMPARATOR
Intervention: Manual titration
Number of subjects: 249

Group type: COMPARATOR
Intervention: Home APAP titration
Number of subjects: 249
Study: 19108595

Group type: EXPERIMENTAL
Intervention: Moderate and deep sedation (MAC) using ketamine-midazolam-propofol anesthetic combination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moderate and deep sedation (MAC)
Number of subjects: 100
Study: 16618562

Group type: EXPERIMENTAL
Intervention: Tolterodine extended release (TER) 4 mg once daily 4 hours or less before bed
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study: 12810615

Group type: EXPERIMENTAL
Intervention: Exercise training (4 weeks duration)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 35
Study: 10782908

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (1 g-0.2 g every 8 h intravenously, then 500 mg-125 mg every 8 h orally)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cefotaxime (1 g every 6 h intravenously)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (for patients on prophylactic norfloxacin)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cefotaxime (for patients on prophylactic norfloxacin)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 96
Study: 8794600

Group type: EXPERIMENTAL
Intervention: Alginate consumption
Number of subjects: 3971

Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 3971

Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy
Number of subjects: 3971
Study: 1428550

Group type: EXPERIMENTAL
Intervention: Retinal Nerve Fiber Layer Defects (RNFL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Slit defects
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Wedge defects
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diffuse defects
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mixed defects
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Location of defects
Number of subjects: 28
Study: 2870124

Group type: COMPARATOR
Intervention: Acebutolol (600 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol (300 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol (100 mg/day)
Number of subjects: 0
Study: 30690288

Group type: EXPERIMENTAL
Intervention: Early Warning Score‐guided proactive rapid response team model
Number of subjects: 12148

Group type: COMPARATOR
Intervention: Rapid response team model based on staff nurse identification of vital sign derangements
Number of subjects: 12148
Study: 30091135

Group type: EXPERIMENTAL
Intervention: Education workshops (Group E1)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard information and medical service (Group E0)
Number of subjects: 201
Study: 27618445

Group type: EXPERIMENTAL
Intervention: Closed vegetation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other landcover categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Landcover refuges under future climate change
Number of subjects: 0
Study: 25245812

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 181

Group type: COMPARATOR
Intervention: IFNβ-1a IM (30 mg weekly)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 22115802

Group type: EXPERIMENTAL
Intervention: Clamp Crushing Technique (CRUSH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection (CUSA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bipolar device (LigaSure)
Number of subjects: 60
Study: 20199265

Group type: EXPERIMENTAL
Intervention: Endovascular treatment of femoropopliteal arteries
Number of subjects: 58
Study: 17531400

Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 258
Study: 16366809

Group type: EXPERIMENTAL
Intervention: Combined family and school intervention condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: School-only condition
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study: 11982840

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (10 microg x kg(‐1)) with 0.5% tetracaine D10 (hyperbaric morphine group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intrathecal morphine mixed with saline after 0.5% tetracaine D10 (hypobaric morphine group)
Number of subjects: 14
Study: 10436095

Group type: EXPERIMENTAL
Intervention: Early CT changes identified by experienced stroke specialists and other physicians
Number of subjects: 70
Study: 9002910

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2137972

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 82
Study: 714380

Group type: EXPERIMENTAL
Intervention: Slow-releasing artificial tears (SR-AT)
Number of subjects: 40
Study: 31365151

Group type: EXPERIMENTAL
Intervention: Tacrolimus/everolimus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tacrolimus/mycophenolate
Number of subjects: 60
Study: 27793063

Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES) strength training in the morning (MTG, 07:00-08:00 h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES) strength training in the evening (ETG, 17:00-18:00 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (MTG and ETG)
Number of subjects: 20
Study: 25241106

Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 42

Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both surfactants
Number of subjects: 42
Study: 23351224

Group type: EXPERIMENTAL
Intervention: At-home bleaching
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Chemically activated office bleaching
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: KTP laser‐activated office bleaching
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no bleaching)
Number of subjects: 96